Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00292487 · ClinicalTrials.gov registry record · Phase 4
Patients With Renal Impairment Undergoing CT
A Phase 4 study, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
NCT00292487 is a Phase 4 study that has completed, run by Bracco Diagnostics. The registered enrollment target is 150 participants.
The verdict
NCT00292487, a Phase 4 study, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with mild to moderate renal impairment who undergo a clinically indicated IV contrast-enhanced (multidetector computed tomography) MDCT of the liver or MDCT angiography of the lower extremities. Serum Creatinine (SCr) will be measured before and up to 48-72 hours post dose.
Interventions
- DRUG Iopamidol 370 mgI/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00292487
The ClinicalTrials.gov registry entry for NCT00292487 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Iopamidol 370 mgI/mL is the first listed.
NCT00292487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00292487 about?
NCT00292487 is a clinical study titled "Patients With Renal Impairment Undergoing CT". The purpose of the study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with mild to moderate renal impairment who undergo a clinically indicated IV contrast-enhanced (multidetector computed tomography) MDCT of the liver...
What is the current status of trial NCT00292487?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2004-11. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00292487?
The interventions under investigation include: Iopamidol 370 mgI/mL (DRUG).
Who is sponsoring clinical trial NCT00292487?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.